Published in Clinical Oncology Week, February 6th, 2006
"The objective of the current study was to compare chemotherapy dose modifications in obese (a body mass index [BMI] >95%) and nonobese (a BMI: 95%) pediatric patients with acute lymphoblastic leukemia (ALL). The study cohort was comprised of 199 pediatric patients diagnosed with ALL who were treated at 1 of 2 South Texas pediatric oncology centers between 1990-2000," scientists in the United States report.
J. Baillargeon and colleagues at the University of Texas explained, "The relative chemotherapy dose modification during the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.